[Adverse effects of leukotriene-antagonists].
Chohnabayashi
Naohiko
N
Department of Respiratory Medicine, St. Luke's International Hospital.
Sugiura
Rika
R
Nishimura
Naoki
N
D000085:Acetates / Q000009:adverse effects*; D000707:Anaphylaxis / Q000139:chemically induced*; D056486:Chemical and Drug Induced Liver Injury; D002867:Chromones / Q000009:adverse effects*; D003521:Cyclopropanes; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000009:adverse effects*; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007211:Indoles; D020024:Leukotriene Antagonists / Q000009:adverse effects*; D016859:Lipoxygenase Inhibitors; D017563:Lung Diseases, Interstitial / Q000139:chemically induced; D008565:Membrane Proteins / Q000037:antagonists & inhibitors*; D048448:Phenylcarbamates; D011804:Quinolines / Q000009:adverse effects*; D018077:Receptors, Leukotriene; D013440:Sulfides; D013449:Sulfonamides; D014105:Tosyl Compounds / Q000009:adverse effects*
D000085:Acetates; D002867:Chromones; D003521:Cyclopropanes; D004791:Enzyme Inhibitors; D007211:Indoles; D020024:Leukotriene Antagonists; D016859:Lipoxygenase Inhibitors; D008565:Membrane Proteins; D048448:Phenylcarbamates; D011804:Quinolines; D018077:Receptors, Leukotriene; D013440:Sulfides; D013449:Sulfonamides; D014105:Tosyl Compounds; C083169:leukotriene D4 receptor; C093875:montelukast; C047681:pranlukast; C062735:zafirlukast